Core Insights - Quantum BioPharma Ltd. has reported significant advancements in its clinical trials and financial performance for the year ended December 31, 2024, including the completion of the unbuzzd™ clinical trial and progress in the Lucid-21-302 Phase 1 trial for multiple sclerosis [1][12][14] Financial Performance - The company reported cash and cash equivalents of 11.1 million USD in 2023 [3] - Operating expenses were reduced to 23.8 million USD in 2023, marking an improvement of over 32% [3] - Net cash used in operations decreased to 10.8 million USD in 2023, reflecting a 36% improvement [4] - The net loss for the year was 18.2 million USD in 2023 [6] Clinical Developments - The unbuzzd™ clinical trial demonstrated that the product significantly accelerated the reduction of Blood Alcohol Concentration (BAC) by over 40% faster within 30 minutes compared to control subjects, while also alleviating symptoms of intoxication and hangover [9][13] - The company has initiated the development of rekvry™, a treatment for alcohol misuse, aimed at addressing unmet healthcare needs [8] - The Lucid-21-302 drug for multiple sclerosis has completed a Phase 1 trial, showing safety and tolerability, and is preparing for a Phase 2 trial [14][16] Strategic Initiatives - Celly Nutrition Corp., the licensee for unbuzzd™, is exploring an initial public offering (IPO) and has engaged a New York investment bank to raise up to 3.5 million worth of Bitcoin and other cryptocurrencies, reflecting a strategic approach to enhance liquidity [16][17] - Quantum BioPharma is focused on expanding the distribution of unbuzzd™ through partnerships and e-commerce initiatives [18]
Quantum Biopharma’s 2024 Financial Statements Show Strong Improvements in Cash, Working Capital, Operating Efficiency and the Removal of Material Uncertainty Related to Going Concern